RYVAX | VENAX | RYVAX / VENAX | |
Total Expense Ratio | 1.65 | 0.09 | 1,833% |
Annual Report Gross Expense Ratio | 1.68 | 0.09 | 1,867% |
Fund Existence | 27 years | 21 years | - |
Gain YTD | -11.726 | 0.937 | -1,251% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 100000 | 3% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 5.01M | 8.68B | 0% |
Annual Yield % from dividends | 0.00 | 3.27 | - |
Returns for 1 year | -25.77 | -4.95 | 521% |
Returns for 3 years | 11.11 | 19.43 | 57% |
Returns for 5 years | 72.70 | 144.85 | 50% |
Returns for 10 years | -61.65 | 23.53 | -262% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
TSMG | 18.84 | 0.57 | +3.12% |
Leverage Shares 2X Long Tsm Daily ETF | |||
BNDD | 12.28 | 0.07 | +0.61% |
Quadratic Deflation ETF | |||
CORP | 96.81 | 0.26 | +0.27% |
PIMCO Investment Grade Corporate Bd ETF | |||
GMAY | 39.61 | 0.07 | +0.18% |
FT Vest U.S. Eq Mod Buffr ETF - May | |||
SBIO | 33.11 | -0.12 | -0.37% |
ALPS Medical Breakthroughs ETF |